🇺🇸 Human Interleukin-11 in United States

75 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 75

Most-reported reactions

1. Platelet Count Decreased — 17 reports (22.67%)
2. Myelosuppression — 14 reports (18.67%)
3. Neutrophil Count Decreased — 8 reports (10.67%)
4. White Blood Cell Count Decreased — 7 reports (9.33%)
5. Anaemia — 6 reports (8%)
6. Pneumonia — 6 reports (8%)
7. Thrombocytopenia — 5 reports (6.67%)
8. Bone Marrow Failure — 4 reports (5.33%)
9. Decreased Appetite — 4 reports (5.33%)
10. Fatigue — 4 reports (5.33%)

Source database →

Frequently asked questions

Is Human Interleukin-11 approved in United States?

Human Interleukin-11 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Human Interleukin-11 in United States?

Jun wang is the originator. The local marketing authorisation holder may differ — check the official source linked above.